tradingkey.logo
搜尋

Evolus Inc

EOLS
添加自選
6.900USD
+0.160+2.37%
收盤 07/02, 13:00美東報價延遲15分鐘
454.29M總市值
虧損本益比TTM

關於 Evolus Inc 公司

Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins and injectable hyaluronic acid gels. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and certain European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe.

Evolus Inc簡介

公司代碼EOLS
公司名稱Evolus Inc
上市日期Feb 08, 2018
CEOMoatazedi (David)
員工數量332
證券類型Ordinary Share
年結日Feb 08
公司地址520 Newport Center Dr Ste 1200
城市NEWPORT BEACH
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編92660-7022
電話19492844555
網址https://www.evolus.com/
公司代碼EOLS
上市日期Feb 08, 2018
CEOMoatazedi (David)

Evolus Inc公司高管

名稱
名稱/職務
職務
持股
持股變動
Mr. Vikram Malik
Mr. Vikram Malik
Independent Chairman of the Board
Independent Chairman of the Board
243.01K
-28.17%
Ms. Tatjana Mitchell
Ms. Tatjana Mitchell
Chief Financial Officer
Chief Financial Officer
226.09K
+53.73%
Mr. David Moatazedi
Mr. David Moatazedi
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
105.11K
-128.12%
Mrs. Brady Stewart
Mrs. Brady Stewart
Independent Director
Independent Director
88.63K
-43.10%
Mr. David N. Gill
Mr. David N. Gill
Independent Director
Independent Director
41.33K
-92.42%
Dr. Rui L. Avelar, M.D.
Dr. Rui L. Avelar, M.D.
Chief Medical Officer, Head - Research and Development
Chief Medical Officer, Head - Research and Development
--
--
Ms. Karah Parschauer, J.D.
Ms. Karah Parschauer, J.D.
Independent Director
Independent Director
--
--
Mr. Nareg Sagherian
Mr. Nareg Sagherian
Investor Relations
Investor Relations
--
--
Mr. Albert G. White, III
Mr. Albert G. White, III
Independent Director
Independent Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Mr. Vikram Malik
Mr. Vikram Malik
Independent Chairman of the Board
Independent Chairman of the Board
243.01K
-28.17%
Ms. Tatjana Mitchell
Ms. Tatjana Mitchell
Chief Financial Officer
Chief Financial Officer
226.09K
+53.73%
Mr. David Moatazedi
Mr. David Moatazedi
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
105.11K
-128.12%
Mrs. Brady Stewart
Mrs. Brady Stewart
Independent Director
Independent Director
88.63K
-43.10%
Mr. David N. Gill
Mr. David N. Gill
Independent Director
Independent Director
41.33K
-92.42%
Dr. Rui L. Avelar, M.D.
Dr. Rui L. Avelar, M.D.
Chief Medical Officer, Head - Research and Development
Chief Medical Officer, Head - Research and Development
--
--

常見問題

Evolus Inc的前五大股東是誰?

Evolus Inc的前五大股東如下:Mr. Vikram Malik

有多少機構持有Evolus Inc(EOLS)的股份?

截至2026Q1,共有391家機構持有Evolus Inc的股份,合計持有的股份價值約為50.03M,占公司總股份的75.98% 。與2025Q4相比,機構持股有所增加,增幅為-16021350.00。